ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)

Stock News

05/06

ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1174217966"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174217966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174217966?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217966","market":"hk","top_or_hot":-1,"title":"ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)","media":"Stock News","content":"<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-06 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1174217966","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217966","pubTimestamp":1778026854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","ECO":"Okeanis Eco Tankers","BK1574":"生物医药B类股","01672":"歌礼制药-B","LU0997586861.USD":"FIDELITY NORDIC \"A\" (USDHDG) ACC","BK4144":"石油与天然气的储存和运输","01477":"欧康维视生物-B"},"translate_title":"歌礼-B(01672)将在第33届欧洲肥胖大会(ECO 2026)上展示多个项目数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ECO":1,"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}